Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
Keyword(s):
Keyword(s):
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. e16016-e16016
Keyword(s):
Keyword(s):
Keyword(s):
2019 ◽
Vol 41
(12)
◽
pp. 2517-2528.e28
◽
Keyword(s):
2020 ◽
Vol 277
(5)
◽
pp. 1437-1448
◽
Keyword(s):